Inflammation Severity and miRNA-126 in Trauma

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMelike Cengiz

About this trial

Trauma triggers a complex immune response intended to eliminate danger signals and restore physiological balance. Early post-traumatic inflammation is primarily initiated by damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). In patients with severe trauma, dysregulated inflammation increases susceptibility to infection, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), and mortality. The lungs are particularly vulnerable, and excessive inflammatory activation may lead to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS), conditions characterized by increased vascular permeability, alveolar epithelial injury, surfactant dysfunction, and impaired gas exchange.

Pro-inflammatory cytokines, activated neutrophils, reactive oxygen species, and proteases contribute to endothelial and epithelial barrier disruption. Recent evidence also suggests that several microRNAs, including miR-126, may play a regulatory role in pulmonary barrier integrity through modulation of tight-junction proteins and PI3K/AKT-related pathways.

Although many components of the trauma-related inflammatory response have been described, the relationship between systemic inflammatory severity and impairment of pulmonary gas exchange remains insufficiently defined in clinical settings.

This study aims to investigate the correlation between inflammatory severity markers (C-reactive protein, procalcitonin, IL-6, reactive oxygen derivatives, neutrophil-to-lymphocyte ratio, lactate), imaging findings (flow-mediated dilation by ultrasound), clinical parameters (blood pressure, heart rate, urine output, vasoactive medication requirements), pulmonary gas-exchange measurements (arterial blood gases, PaO₂/FiO₂ ratio), and circulating miRNA-126 levels in trauma patients. The findings may help identify biomarkers that better reflect inflammatory burden and the risk of lung dysfunction following trauma.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Adult patients (≥18 years) admitted to the anesthesia intensive care units of Akdeniz University Faculty of Medicine with blunt or penetrating trauma. The population represents early post-traumatic ICU admissions without thoracic injury, pre-existing infection, immunodeficiency, or other conditions that may alter the inflammatory response.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

130 Participants
are grouped into 3 trial groups
Group A: Patients with ARDS and Were Followed in ICU After Trauma
Group B: Patients without ARDS and Were Followed in ICU After Trauma
Group C: Control Group

Trial outcomes

Primary outcomes

1

Correlation Between Serum miRNA-126 Levels and Severity of Lung Injury

Measurement of circulating miRNA-126 levels and their correlation with pulmonary gas-exchange impairment (PaO₂/FiO₂ ratio, arterial blood gas parameters).

Time frame
First 3 days of ICU admission.

Secondary outcomes

1

Serum IL-6 and Syndecan Levels

Daily blood sampling for measurement of IL-6 and Syndecan as markers of systemic inflammation and endothelial injury.

Time frame
First 3 days of ICU admission.
2

Flow-Mediated Dilation (FMD) by Ultrasound

Assessment of endothelial function by measuring brachial artery flow-mediated dilation.

Time frame
Within first 3 days of ICU admission.

Other outcomes

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

Akdeniz University HospitalRecruiting04200, Antalya, AğrıTurkey (Türkiye)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Melike Cengiz

Lead sponsor

Akdeniz University

Sponsor institution